At a glance
- Originator Millennium Pharmaceuticals
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
- 05 Nov 1999 ProScript has been acquired by LeukoSite
- 14 Sep 1998 New profile